BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol 2018;30:32-8. [PMID: 29454995 DOI: 10.1016/j.coviro.2018.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Hu J, Protzer U, Siddiqui A. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. J Virol 2019;93:e01032-19. [PMID: 31375584 DOI: 10.1128/JVI.01032-19] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
2 Cortese MF, González C, Gregori J, Casillas R, Carioti L, Guerrero-Murillo M, Riveiro-Barciela M, Godoy C, Sopena S, Yll M, Quer J, Rando A, Lopez-Martinez R, Pacín Ruiz B, García-García S, Esteban-Mur R, Tabernero D, Buti M, Rodríguez-Frías F. Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients. Sci Rep 2021;11:4215. [PMID: 33603102 DOI: 10.1038/s41598-021-83762-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
5 Park S, Ha YN, Dezhbord M, Lee AR, Park ES, Park YK, Won J, Kim NY, Choo SY, Shin JJ, Ahn CH, Kim KH. Suppression of Hepatocyte Nuclear Factor 4 α by Long-term Infection of Hepatitis B Virus Contributes to Tumor Cell Proliferation. Int J Mol Sci 2020;21:E948. [PMID: 32023898 DOI: 10.3390/ijms21030948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
7 Wei L, Ploss A. Mechanism of Hepatitis B Virus cccDNA Formation. Viruses 2021;13:1463. [PMID: 34452329 DOI: 10.3390/v13081463] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Urban S, Bertoletti A. Editorial overview: Antiviral strategies: Virological and immunological basis for HBV cure. Curr Opin Virol 2018;30:iv-vi. [PMID: 29866361 DOI: 10.1016/j.coviro.2018.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Omagari K, Asamitsu K, Tanaka Y. Application of fluorescent-based technology detecting protein-protein interactions to monitor the binding of hepatitis B virus X protein to DNA-damage-binding protein 1. Biophys Physicobiol 2021;18:67-77. [PMID: 33977004 DOI: 10.2142/biophysico.bppb-v18.008] [Reference Citation Analysis]
10 Yuan H, Zhao L, Yuan Y, Yun H, Zheng W, Geng Y, Yang G, Wang Y, Zhao M, Zhang X. HBx represses WDR77 to enhance HBV replication by DDB1-mediated WDR77 degradation in the liver. Theranostics 2021;11:8362-78. [PMID: 34373747 DOI: 10.7150/thno.57531] [Reference Citation Analysis]
11 Zhang TY, Chen HY, Cao JL, Xiong HL, Mo XB, Li TL, Kang XZ, Zhao JH, Yin B, Zhao X, Huang CH, Yuan Q, Xue D, Xia NS, Yuan YA. Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nat Commun 2019;10:3192. [PMID: 31324803 DOI: 10.1038/s41467-019-11173-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
12 Ho JK, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses 2020;12:E126. [PMID: 31973017 DOI: 10.3390/v12020126] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
13 Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin Microbiol Infect 2019;25:906.e1-7. [PMID: 30472417 DOI: 10.1016/j.cmi.2018.11.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget 2021;12:2421-33. [PMID: 34853663 DOI: 10.18632/oncotarget.28077] [Reference Citation Analysis]
15 Hodge K, Makjaroen J, Robinson J, Khoomrung S, Pisitkun T. Deep Proteomic Deconvolution of Interferons and HBV Transfection Effects on a Hepatoblastoma Cell Line. ACS Omega 2020;5:16796-810. [PMID: 32685848 DOI: 10.1021/acsomega.0c01865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Arslan F, Franci G, Maria Nastri B, Pagliano P. Hepatitis B virus-induced hepatocarcinogenesis: A virological and oncological perspective. J Viral Hepat 2021;28:1104-9. [PMID: 34003561 DOI: 10.1111/jvh.13551] [Reference Citation Analysis]
17 Glebe D, Goldmann N, Lauber C, Seitz S. HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals. Antiviral Res 2021;186:104973. [PMID: 33166575 DOI: 10.1016/j.antiviral.2020.104973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zhang X, Wang L, Yan Y. Identification of potential key genes and pathways in hepatitis B virus-associated hepatocellular carcinoma by bioinformatics analyses. Oncol Lett. 2020;19:3477-3486. [PMID: 32269621 DOI: 10.3892/ol.2020.11470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Magon KL, Parish JL. From infection to cancer: how DNA tumour viruses alter host cell central carbon and lipid metabolism. Open Biol 2021;11:210004. [PMID: 33653084 DOI: 10.1098/rsob.210004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Shen B, Chen Y, Hu J, Qiao M, Ren J, Chen J, Tang N, Huang A, Hu Y. Hepatitis B virus X protein modulates upregulation of DHX9 to promote viral DNA replication. Cell Microbiol. 2020;22:e13148. [PMID: 31829498 DOI: 10.1111/cmi.13148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Fogeron M, Lecoq L, Cole L, Montserret R, David G, Page A, Delolme F, Nassal M, Böckmann A. Phosphorylation of the Hepatitis B Virus Large Envelope Protein. Front Mol Biosci 2022;8:821755. [DOI: 10.3389/fmolb.2021.821755] [Reference Citation Analysis]
22 Gaglia MM, Munger K. More than just oncogenes: mechanisms of tumorigenesis by human viruses. Curr Opin Virol 2018;32:48-59. [PMID: 30268926 DOI: 10.1016/j.coviro.2018.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
23 Iarovaia OV, Ioudinkova ES, Velichko AK, Razin SV. Manipulation of Cellular Processes via Nucleolus Hijaking in the Course of Viral Infection in Mammals. Cells 2021;10:1597. [PMID: 34202380 DOI: 10.3390/cells10071597] [Reference Citation Analysis]
24 Liu T, Li W, Zhang Y, Siyin ST, Zhang Q, Song M, Zhang K, Liu S, Shi H. Associations between hepatitis B virus infection and risk of colorectal Cancer: a population-based prospective study. BMC Cancer 2021;21:1119. [PMID: 34663268 DOI: 10.1186/s12885-021-08846-w] [Reference Citation Analysis]
25 Mao X, Tey SK, Ko FCF, Kwong EML, Gao Y, Ng IO, Cheung ST, Guan X, Yam JWP. C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Letters 2019;444:60-9. [DOI: 10.1016/j.canlet.2018.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
26 Niepmann M, Gerresheim GK. Hepatitis C Virus Translation Regulation. Int J Mol Sci. 2020;21. [PMID: 32230899 DOI: 10.3390/ijms21072328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
27 Yang MH, Chen M, Mo HH, Tsai WC, Chang YC, Chang CC, Chen KC, Wu HY, Yuan CH, Lee CH, Chen YA, Tyan YC. Utilizing Experimental Mouse Model to Identify Effectors of Hepatocellular Carcinoma Induced by HBx Antigen. Cancers (Basel) 2020;12:E409. [PMID: 32050622 DOI: 10.3390/cancers12020409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
28 Gao Y, Gu J, Wang Y, Fu D, Zhang W, Zheng G, Wang X. Hepatitis B virus X protein boosts hepatocellular carcinoma progression by downregulating microRNA-137. Pathol Res Pract 2020;216:152981. [PMID: 32527447 DOI: 10.1016/j.prp.2020.152981] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Li SK, Tang HC, Man-Hon Leung M, Zou W, Chan WL, Zhou Y, Oi-Lin Ng I, Ching YP. Centrosomal protein TAX1BP2 inhibits centrosome-microtubules aberrations induced by hepatitis B virus X oncoprotein. Cancer Lett 2020;492:147-61. [PMID: 32827601 DOI: 10.1016/j.canlet.2020.08.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Kim HJ, Kim OH, Hong HE, Lee SC, Kim SJ. Harnessing adipose‑derived stem cells to release specialized secretome for the treatment of hepatitis B. Int J Mol Med 2021;47:15. [PMID: 33448314 DOI: 10.3892/ijmm.2021.4848] [Reference Citation Analysis]
31 Zhang X, Ma L, Zhai L, Chen D, Li Y, Shang Z, Zhang Z, Gao Y, Yang W, Li Y, Pan Y. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. Int J Med Sci 2021;18:984-99. [PMID: 33456356 DOI: 10.7150/ijms.49126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Hernández S, Álvarez-Astudillo F, Garrido D, Prieto C, Loyola A, Villanueva RA. Canonical and Divergent N-Terminal HBx Isoform Proteins Unveiled: Characteristics and Roles during HBV Replication. Biomedicines 2021;9:1701. [PMID: 34829930 DOI: 10.3390/biomedicines9111701] [Reference Citation Analysis]
33 Zhang J, Ling N, Lei Y, Peng M, Hu P, Chen M. Multifaceted Interaction Between Hepatitis B Virus Infection and Lipid Metabolism in Hepatocytes: A Potential Target of Antiviral Therapy for Chronic Hepatitis B. Front Microbiol 2021;12:636897. [PMID: 33776969 DOI: 10.3389/fmicb.2021.636897] [Reference Citation Analysis]
34 Kuo CY, Chiu V, Hsieh PC, Huang CY, Huang SJ, Tzeng IS, Tsai FM, Chen ML, Liu CT, Chen YR. Chrysophanol attenuates hepatitis B virus X protein-induced hepatic stellate cell fibrosis by regulating endoplasmic reticulum stress and ferroptosis. J Pharmacol Sci 2020;144:172-82. [PMID: 32811746 DOI: 10.1016/j.jphs.2020.07.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
35 Xu F, Song H, An B, Xiao Q, Cheng G, Tan G. NF-κB-Dependent IFIT3 Induction by HBx Promotes Hepatitis B Virus Replication. Front Microbiol 2019;10:2382. [PMID: 31681236 DOI: 10.3389/fmicb.2019.02382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Wang X, Huo B, Liu J, Huang X, Zhang S, Feng T. Hepatitis B virus X reduces hepatocyte apoptosis and promotes cell cycle progression through the Akt/mTOR pathway in vivo. Gene 2019;691:87-95. [PMID: 30630095 DOI: 10.1016/j.gene.2018.12.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
37 Gao L, Yang J, Feng J, Liu Z, Dong Y, Luo J, Yu L, Wang J, Fan H, Ma W, Liu T. PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication. Front Immunol 2022;13:856463. [DOI: 10.3389/fimmu.2022.856463] [Reference Citation Analysis]
38 Li X, Liu X, Wang W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Front Cell Dev Biol 2021;9:614847. [PMID: 33777929 DOI: 10.3389/fcell.2021.614847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Minor MM, Hollinger FB, McNees AL, Jung SY, Jain A, Hyser JM, Bissig KD, Slagle BL. Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex. Cells. 2020;9. [PMID: 32235678 DOI: 10.3390/cells9040834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]